ASCO GUIDELINES Bundle

PARP Inhibitors in the Management of Ovarian Cancer

ASCO GUIDELINES App Bundle brought to you fcourtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: http://eguideline.guidelinecentral.com/i/1475496

Contents of this Issue

Navigation

Page 7 of 7

106 Commerce Street, Suite 105 Lake Mary, FL 32746 TEL: 407.878.7606 • FAX: 407.878.7611 For additional copies, order at GuidelineCentral.com Copyright © 2020 All rights reserved ASCOPARP08203 Disclaimer is pocket guide is derived om recommendations in the American Society of Clinical Oncology Guideline. is resource is a practice tool based on ASCO ® practice guidelines and is not intended to substitute for the independent professional judgment of the treating physician. Practice guidelines do not account for individual variation among patients. is pocket guide does not purport to suggest any particular course of medical treatment. Use of the practice guidelines and this resource are voluntary. e practice guidelines and additional information are available at www.asco.org/ gynecologic-cancer-guidelines. Copyright © 2020 by American Society of Clinical Oncology. All rights reserved. Abbreviations ASCO, American Society of Clinical Oncolog y; CT, carboplatin and paclitaxel; BRCAm, BRCA1/2 mutation; BRCAwt, BRCA1/2 wild-type; EOC, epithelial ovarian cancer; PARPi, poly(ADP-ribose) polymerase inhibitors Source William P. Tew, MD; Christina Lacchetti, MHSc; Annie Ellis, et al. (2020). PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline. J Clin Oncol, doi: 10.1200/ JCO.20.01924 Recommendation Grading Type Benefit/harm Evidence Quality Strength of Recommendation EB Evidence- based B Benefits outweigh harms H High Strong CB Consensus- based H Harms outweigh benefits I Intermediate Moderate IC Informal consensus B/H Benefit equals harm L Low Weak NB No benefit Ins Insufficient ASCO believes that cancer clinical trials are vital to inform medical decisions and improve cancer care and that all patients should have the opportunity to participate. Additional information, which may include data supplements, slide sets, and other clinical tools and resources, is available at www.asco.org/g ynecologic-cancer-guidelines.

Articles in this issue

Links on this page

Archives of this issue

view archives of ASCO GUIDELINES Bundle - PARP Inhibitors in the Management of Ovarian Cancer